A preliminary study on natural killer activity in0 patients with gynecologic malignancies

Abstract

A release assay of¹²⁵IUdR-labelled K562 cells as target cells was performed for measuring natural killer (NK) activity of mononuclear cells in the peripheral blood of 92 cases, including 42 healthy women, 22 patients with gynecological benign tumors, and 28 patients with gynecological malignancies. The NK activity of malignant tumor group was obviously lower than that of healthy women and of benign tumor group, suggesting that a defective NK activity was present in the patients with gynecological malignancies. The NK activity in patients with ovarian malignant tumors was much lower than in those with cervical cancer, the difference being of statistical significance. In this study the leukocyte interferon was investigated for its effects on the NK activity of peripheral blood mononuclear cells from 4 cases of gynecological malignancies. The level of NK activity ascended significantly in every case nearly to normal. The augmentation of NK activity by interferon may be used as a new immunotherapy for gynecological malignancies.

Keywords

gynecologic malignancies / NK activity / interferon

References

[1] (NK) I. 125IUdR NK, 1983, 3: 272-7

[2] HallerO, et al. . Role of non-conventional natural killer cells in resistance against syngeneic tumor cells in vivo. Nature, 1977, 270: 609-11

[3] ShauH, et al. . Human natural killing against ovarian carcinoma. Br J Cancer, 1988, 47: 687-95

[4] HerbermanRH, et al. . Natural killer cell: heir role in defenses against disease. Science, 1981, 214: 24-30

[5] RiesenfeldI, et al. . Positive correlation between in vitro NK activity and in vivo resistance towards AKR lymphoma cells. Int J Cancer, 1980, 25: 399-403

[6] TalmadgeJE, et al. . Role of NK cells in tumour growth and metastasis in beige mice. Nature, 1980, 284: 622-4

[7] KassaiM, et al. . Direct evidence that natural killer cells in nonimmune spleen cell populations prevent tumor growth in vivo. J Exp Med, 1979, 149: 1260-4

[8] 1984;3: 103–5.

[9] 1985;2:83–6.

[10] SchattnerA, et al. . Natural killer cells —toward clinical application. Am J Hematol, 1985, 18: 435-43

[11] HamiltonTC, et al. . Biologic therapy for treatment of malignant common epithelial tumors of the ovary. Cancer, 1987, 60(8 suppl): 2054-63

[12] LotzowaE, et al. . Recombinant IL-2-activated NK cells mediate LAK activity against ovarian cancer. Int J Cancer, 1988, 43: 225-31

[13] LichtensteinA, et al. . Intraperitoneal administration of human recombinant interferon-α in patients with ovarian cancer: effects on lymphocyte phenotype and cytotoxicity. Cancer Res, 1988, 48: 5853-9

[14] BoyerPJ, et al. . Lymphocyte activation by recombinant interleukin-2 in ovarian cancer patients. Obstet Gynecol, 1989, 73: 793-7